Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Cu2O-mediated regio- and stereoselective one-pot synthesis of (Z)-3-ylidenephthalides from 2-iodobenzoic acids and terminal alkynes

Ahmed R. Aliab and Longqin Hu*ac
aDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, USA. E-mail: LongHu@pharmacy.rutgers.edu
bDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
cRutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA

Received 15th May 2025 , Accepted 29th July 2025

First published on 31st July 2025


Abstract

A series of substituted (Z)-3-ylidenephthalides was synthesized from 2-iodobenzoic acids and various terminal alkynes in the presence of Cu2O in DMF at 100–130 °C. Our copper(I) oxide-catalyzed reaction requires no additional palladium, ligand, or base, making it an economical and efficient process. This optimized method is applicable to a range of 2-iodobenzoic acids and alkynes with diverse electronic, steric, and stability characteristics.


Introduction

Phthalides, particularly (Z)-3-ylidenephthalides, are crucial oxygen-containing heterocyclic compounds.1 They're found in natural products like thunberginol F,2 senkyunolide E,3 and dactylicapnosine,4 and in synthetic compounds with various biological activities, including anti-coagulant, anti-diabetic, and anti-HIV properties (Fig. 1).5 C3-alkylphthalides, such as cytosporone E,6 cryphonectric acid,7 and fuscinarin,8 are also important in complex natural product synthesis.9 Furthermore, (Z)-3-ylidenephthalides are valuable synthetic intermediates;10 for instance, benzylidenephthalide can be converted to phthalazinone, a key precursor to Olaparib, a drug for advanced ovarian cancer.11 Phthalides also contain a furan-2-(5H)-one framework, a common feature in many biologically active molecules like rofecoxib.12
image file: d5ob00808e-f1.tif
Fig. 1 Examples of natural or synthetic phthalides/furanones with biological activity.

C–C coupling formation is crucial in the synthesis of pharmaceuticals and natural products.13 The Sonogashira reaction is a widely used method for forming C(sp2)–C(sp) and (sp3)–C(sp) bonds through the cross-coupling of terminal alkynes with aryl/alkyl halides, typically using Pd/Cu or Pd complexes as catalysts.14 To reduce costs, research has focused on replacing palladium with more affordable metals like nickel, iron, and copper. While copper, with ligands such as 1,10-phenanthroline, 1,3-diketone, and DABCO, can catalyze Pd-free Sonogashira reactions, these methods often require excessive amounts of ligands or elevated temperatures.15

As shown in Scheme 1, many methods exist for the preparation of (Z)-3-ylidenephthalides including (a) modified Perkin, Wittig or Julia reaction on phthalic anhydride;16 (b) condensation of phthalic anhydride with phenylacetic acid;17 (c) condensation of phthaloyl dichloride with 1,3-dicarbonyl compounds or silyl enol ethers;18 (d) cyclization of 2-allyl- or 2-alkenylbenzoic acid derivatives;19 (e) TSTU or AlCl3-mediated intramolecular cyclization of 2-acylbenzoic acids;20 (f) nickel/palladium-catalyzed isocyanide insertion on 2-haloacetophenones;21 (g) CO insertion in palladium-catalyzed reactions of 2-halo or 2-triflyloxyacetophenones;22 (h) Rh- or Pd-catalyzed tandem coupling and oxidative cyclization of benzoic acids with alkenes or terminal alkynes;23 (i) Pd-free, base-free, Sonogashira-type coupling cyclization reaction on hypervalent iodine(III) five-membered heterocycles;24 (j) NaClO2 or N-heterocyclic carbenes-mediated oxidative cyclization of 2-alkynylbenzaldehydes;25 (k) domino gold-catalyzed cyclization and hydrolysis of 2-alkynyl-N-methoxylbenzamides;26 (l) cyclization of 2-alkynylbenzoic acids catalyzed by transition-metal (Pd, Cu, Ag, Au, or Rh),3b,27 halogens,28 or various base such as DBU, Et3N and KOAc;29 (m) copper-catalyzed tandem decarboxylative cross coupling–cyclization reactions of 2-iodobenzoic acids and arylpropiolic acids;30 and (n) transition-metal-catalyzed tandem coupling–cyclization reactions of 2-halobenzoic acids with terminal alkynes.30b,31


image file: d5ob00808e-s1.tif
Scheme 1 Synthetic pathways reported previously for 3-ylidenephthalides.

As shown in Fig. 2, metal-catalyzed intramolecular cyclizations of 2-alkynylbenzoic acids typically yield both the desired phthalide and the closely related isocoumarin scaffold. Baldwin's rules suggest that both 5-exo-dig and 6-endo-dig cyclization modes are favored, making selective phthalide synthesis challenging.32 Regio- and stereocontrol are crucial for synthesizing pharmaceutically relevant molecules. Few reports describe regioselective phthalide (5-exo-dig) cyclization promoted by Cu2+-NCS catalysis,33 weak bases,29a and temperature control.30b While methods for preparing (Z)-3-ylidenephthalides exist, improved synthetic strategies are needed. Ideal methods would avoid expensive metal-catalysts, simplify purification procedures, minimize regio- or stereoisomerization, reduce side product formation, and provide high yields. Cost-effective coupling reagents are essential for practical industrial applications. Therefore, developing an efficient and economical protocol for the stereoselective synthesis of (Z)-3-ylidenephthalides remains important. Catalytic domino reactions offer a promising approach by minimizing solvent and reagent use, reaction time, purification steps, waste, and cost.


image file: d5ob00808e-f2.tif
Fig. 2 Two possible cyclization pathways leading to either 3-ylidenephthalides (5-exo-dig) or 3-substituted isocoumarins (6-endo-dig).

Building on our recent one-pot indole synthesis,34 we envisioned a similar approach for the selective synthesis of (Z)-3-ylidenephthalides from 2-iodobenzoic acids (Fig. 2). We hypothesize that coupling between 2-iodobenzoic acids and terminal alkynes would generate 2-alkynylbenzoic acids in situ, which would then undergo Cu(I)-mediated intramolecular cyclization to yield (Z)-3-ylidenephthalide. This method offers several significant advantages: (i) selective access to (Z)-3-ylidenephthalides from the similar starting materials by simply changing the nucleophile from methylsulfonamido to carboxylic acid; (ii) the commercial availability and reasonable cost of 2-iodobenzoic acids and their substituted analogs, along with established methods for selective ortho-iodination of benzoic acid derivatives;35 (iii) a simple one-pot reaction and work-up procedure; and (iv) using a copper catalyst without ligands, bases or expensive palladium catalysts for C(sp)–C(sp2) bond formation, enabling cost effective large scale production. To our knowledge, a Cu2O-mediated tandem coupling–cyclization sequence for (Z)-3-ylidenephthalide synthesis has not been previously reported.

Results and discussion

Optimization of the reaction conditions

Building on our previous work on converting 2-iodo-N-mesylanilines to indoles under mild and economical coupling/cyclization conditions,34 we explored extending this method to the synthesis of functionalized phthalides by replacing the methylsulfonamido group with a carboxylic acid group ortho to the iodo group. Inspired by the Castro–Stephens coupling, we chose a copper(I)-catalyzed sequence. To avoid synthesizing and isolating copper(I) acetylide as Castro–Stephens reaction, we sought a palladium-free one-pot synthesis of 3-ylidenephthalides in DMF. As Castro et al. demonstrated DMF's effectiveness for reactions between 2-iodobenzoic acid and copper(I) acetylide,27c,36 we adopted it in our initial screening.

Initially, we chose the coupling of 2-iodobenzoic acid (1a) with ethyl propiolate as a model reaction. As shown in Table 1, the reaction with copper(I) oxide in DMF at 100 °C showed partial conversion of 1a after 4 h (entry 1), as monitored by TLC and HPLC. Extending the reaction time to 6 and 8 h (entries 2 and 3) resulted in 90% conversion to the desired product 2a as the sole product (Table 1, entry 3). (E)-5-Exo/6-endo products were not detected under the reaction conditions. Switching to different copper species, including Cu(0), Cu(I) or Cu(II) (entries 4–10), yielded no product; only starting material remained. Similarly, employing methanol, tert-butanol, THF, dioxane, 1,2-dimethoxyethane, acetonitrile, or toluene as solvents (entries 11–17) resulted in either moderate or no conversion of 1a. The results confirmed DMF as the optimal solvent, providing 90% conversion. Attempts to decrease catalyst loading, shorten reaction time, or change the solvent significantly diminished conversion.

Table 1 Screening of the reaction conditionsa

image file: d5ob00808e-u1.tif

Entry Catalyst Solvent Time (h) %conversionb
a Reactions were performed on a 0.1 mmol scale with the indicated catalyst (30 mol%) and solvent (0.5 mL) at 100 °C in sealed pressure-relief borosilicate glass vials.b Yields of conversion were based on HPLC.c No reaction.
1 Cu2O DMF 4 62
2 Cu2O DMF 6 75
3 Cu2O DMF 8 90
4 CuCl DMF 8 N.R.c
5 CuBr DMF 8 N.R.
6 CuI DMF 8 N.R.
7 Cu(OAc)2 DMF 8 N.R.
8 CuSO4 DMF 8 N.R.
9 Cu(OTf)2 DMF 8 N.R.
10 Cu DMF 8 N.R.
11 Cu2O MeOH 8 N.R.
12 Cu2O t-BuOH 8 13
13 Cu2O THF 8 23
14 Cu2O Dioxane 8 42
15 Cu2O DME 8 39
16 Cu2O MeCN 8 31
17 Cu2O PhMe 8 11


Spectral data for 2a, compared with literature reports, confirmed the presence of an exocyclic double bond with Z geometry. 1H and 13C-NMR chemical shifts clearly distinguish between 5-exo-dig and 6-endo-dig cyclization, and between (Z)- and (E)-3-ylidenephthalides.37 For 6-endo-dig cyclization leading to isocoumarin, HB resonates as a sharp singlet around 7.41 ppm.38 In phthalides, HB appears at 6.39 ppm, consistent with the reported (Z)- and (E)-3-ylidenephthalides (6.51 and 6.33 ppm, respectively). The Z configuration is further supported by the chemical shift of the aromatic proton HA. This proton is significantly deshielded in the E isomer (8.94 ppm) compared to the Z isomer (8.34 ppm).37 Our observed chemical shift at 8.23 ppm strongly indicates the Z configuration. These data confirm the copper(I) oxide-mediated reaction of 2-iodobenzoic acid with ethyl propiolate yields (Z)-3-ylidenephthalides. Under our optimized conditions (30 mol% Cu2O in DMF, without base or ligand), this process exhibits both regio- and stereoselectivity, generating (Z)-3-ylidenephthalides in high yield.

Effect of aryl substitutions on coupling of 2-iodobenzoic acids with ethyl propiolate

Having optimized our reaction conditions, we investigated the generality and scope of the method. Various electron donating and electron withdrawing substituents at R1, R2, R3 and R4 were well tolerated. As shown in Table 2, substrates with electron-donating or electron-withdrawing groups at various positions on the aromatic ring generated the corresponding phthalides (2b–2q) in good to excellent yields with excellent stereoselectivity (entries 2–17). However, substrates with functional groups ortho to either the iodo- or the carboxylic acid group exhibited decreased reactivity, as demonstrated by lower yields in case of a fluoro group ortho to the iodo group (entry 2) or substituents adjacent to the free –COOH group (entries 14–17). Despite this steric hindrance, substrates 1b and 1n–1q still afforded the 5-exo-dig cyclization product in good yield.
Table 2 Scope of 3-ylidenephthalide derivatives from 2-iodobenzoic acids with ethyl propiolatea

image file: d5ob00808e-u2.tif

Entry Subs./prod. R1 R2 R3 R4 Yieldb (%)
a Reactions were carried out in pressure-relief borosilicate glass vials.b Isolated yields.
1 1a/2a –H –H –H –H 82
2 1b/2b –F –H –H –H 69
3 1c/2c –H –F –H –H 83
4 1d/2d –H –Cl –H –H 82
5 1e/2e –H –NO2 –H –H 79
6 1f/2f –H –OCH3 –H –H 74
7 1g/2g –H –OCH3 –OCH3 –H 72
8 1h/2h –H –CF3 –H –H 83
9 1i/2i –H –H –F –H 80
10 1j/2j –H –H –Cl –H 76
11 1k/2k –H –H –Br –H 71
12 1l/2l –H –H –CH3 –H 82
13 1m/2m –H –H –OCH3 –H 74
14 1n/2n –H –H –H –F 71
15 1o/2o –H –H –H –Cl 72
16 1p/2p –H –H –H –CH3 69
17 1q/2q –H –H –H –CF3 70


Within Table 2, electron-donating methoxy groups (entries 6, 7 and 13) appeared to decrease reactivity compared to electron withdrawing groups (entries 3–5 and 8–10). Substrates with bromo substituents on the aromatic ring (entry 11) also showed reduced yields, likely due to potential C–C coupling at the C–Br bond. A key advantage of our metal-catalyzed 3-ylidenephthalide synthesis, starting from 2-iodobenzoic acid, is its regioselectivity compared to methods using benzoic acid derivatives. This is particularly relevant for meta-substituted benzoic acids like 1i–1m (entries 9–13, Table 2), which would likely produce regioisomeric mixtures with other approaches. Using 2-iodo-5-substituted benzoic acid precursors, our method efficiently generates the desired 3-ylidenephthalides 2i–2m in high yields (71–82%) via selective C–C bond formation with ethyl propiolate and subsequent C–O cyclization. Notably, our approach accommodates both electron-donating and electron-withdrawing substituents, demonstrating its broad applicability for efficient and economical synthesis of multi-substituted 3-ylidenephthalides.

Effects of various alkynes on the formation of (Z)-3-ylidenephthalides

Having investigated the effect of substitutions on 2-iodobenzoic acids, we explored the scope and generality of this coupling–cyclization reaction method with various commercially available terminal alkynes. As shown in Table 3, using our optimized Cu2O-catalyzed method, we prepared 3-ylidenephthalides bearing phenylidene (entries 1–9), hydroxyalkylidene (entries 10–19 and 28–31), Boc-aminoalkylidene (entries 20–23), TIPS-alkylidene (entries 24–27), and oxoalkylidene (entries 32–36) substituents at C-3 position of phthalide in good to excellent yields. Our approach directly converts readily available alkynes and 2-iodobenzoic acids into the desired (Z)-3-ylidenephthalides in 53–81% yield, in contrast to Castro–Stephens coupling, which primarily uses phenylacetylene and requires a separate step to generate copper(I) acetylide.
Table 3 Scope of diverse alkynes used to synthesize 3-ylidenephthalides via our Cu2O-catalyzed methoda

image file: d5ob00808e-u3.tif

Entry Subs./prod. R1 R2 R3 Reaction temperature (°C) Time (h) Yieldb (%)
a All reactions were carried out in pressure-relief borosilicate glass vials at the temperature and for the duration indicated.b Isolated yields.
1 1a/3a –H –H –Ph 110 8 81
2 1i/3b –H –F       79
3 1j/3c –H –Cl       79
4 1k/3d –H –Br       70
5 1m/3e –H –CH3       79
6 1n/3f –H –OCH3       75
7 1g/3g –OCH3 –OCH3       71
8 1d/3h –Cl –H       71
9 1t/3i –Br –H       71
10 1a/3j –H –H –CH2OH 120 12 73
11 1k/3k –H –Br       63
12 1m/3l –H –CH3       70
13 1n/3m –H –OCH3       62
14 1g/3n –OCH3 –OCH3       61
15 1d/3o –Cl –H       60
16 1a/3p –H –H –CH2CH2OH 120 12 75
17 1m/3q –H –CH3       72
18 1n/3r –H –OCH3       68
19 1g/3s –OCH3 –OCH3       71
20 1a/3t –H –H –CH2NH–Boc 120 12 78
21 1m/3u –H –CH3       81
22 1n/3v –H –OCH3       73
23 1g/3w –OCH3 –OCH3       73
24 1a/3x –H –H –TIPS 130 18 77
25 1m/3y –H –CH3       76
26 1n/3z –H –OCH3       72
27 1g/3aa –OCH3 –OCH3       71
28 1a/3ab –H –H –CH2CHOHCH3 120 12 71
29 1m/3ac –H –CH3       61
30 1n/3ad –H –OCH3       58
31 1t/3ae –Br –H       53
32 1a/3af –H –H –COCH3 100 8 78
33 1i/3ag –H –F       80
34 1j/3ah –H –Cl       79
35 1m/3ai –H –CH3       79
36 1n/3aj –H –OCH3       72


The alkynes employed showed excellent compatibility with various aryl substituents, both electron-donating or electron-withdrawing. While the synthesis of hydroxyalkylidene derivatives (entries 10–19 and 28–31) has received limited attention in the literature, this work, to our knowledge, represents the first synthesis of Boc-aminoalkylidene (entries 20–23) and oxoalkylidene (entries 32–36) derivatives. Furthermore, it is the first instance of introducing a protected acetylene moiety (entries 24–27) to 2-iodobenzoic acid substrates using a non-palladium catalyzed method. Our simplified tandem reaction efficiently generated (Z)-3-ylidenephthalides 3a–3aj (Table 3). These products, possessing diverse substituents at the 3-position, are valuable building blocks for more complex phthalide-based compounds.

Coupling with phenylacetylene proceeded smoothly, exclusively yielding the (Z)-5-exo-dig products (3a–3i). The structure of (Z)-3-benzylidenephtahalide (3a) was confirmed by extensive 1D and 2D NMR analysis (COSY, HSQC, HMBC, NOESY and APT; SI). A peak at 166.3 ppm, characteristic of 5-membered lactone (more deshielded than 6-membered isocoumarin lactone), was observed in its 13C-NMR. The HB proton at 6.92 ppm showed four HMBC correlations: two with quaternary carbons at 140.1 and 144.2 ppm, and two with tertiary aromatic carbons at 129.7 and 130.3 ppm. The latter two peaks, assigned to the phenyl ring from phenylacetylene, confirm the formation of a 3-ylidenephthalide, not an isocoumarin. The Z configuration was assigned based on NOESY spectra (SI), which showed two correlations between the HB proton and two doublet signals. Reactions with phenylacetylene generally proceeded well (entries 1–9, Table 3), with higher yields observed for 2-iodobenzoic acids with electron-withdrawing groups compared to those with electron-donating groups.

Phthalides with 3-hydroxyalkylidene substituent (entries 10–19 and 28–31, Table 3) were obtained in lower yields compared to those derived from alkynes bearing electron withdrawing groups (e.g., ethyl propiolate or phenylacetylene). This suggests that our coupling/cyclization is more efficient with electron-deficient alkynes. Within the 3-hydroxyalkylidenephthalide series, higher yields were still observed with 2-iodobenzoic acids bearing electron-withdrawing groups. The structures were confirmed by 1D and 2D NMR analysis (SI). A COSY correlation between HB and neighboring aliphatic protons ruled out isocoumarin (6-endo-dig) formation. Furthermore, the vinylic HB proton showed 3–4 HMBC correlations, confirming the installation of the hydroxyalkylidene moiety and phthalide ring formation. A NOESY correlation between HA and HB also supported the assigned Z-isomer structure.

Coupling with N-Boc-propargylamine (entries 20–23, Table 3) gave slightly higher yields than the 3-hydroxyalkylidenephthalides. This may be attributed to the masked hydroxyl group and protected amine, which could reduce chelation with the Cu(I) species, a potential factor contributing to lower yields in the 3-hydroxyalkylidenephthalides synthesis. Trimethylsilylacetylene did not afford the desired phthalide. However, using the more stable triisopropylsilylacetylene, corresponding products were obtained in 71–77% yields without desilylation (entries 24–27, Table 3). The structure of 3x (entry 24) was confirmed by 1D and 2D NMR analysis (SI). Two HMBC correlations were observed between HB proton and the isopropylene and quaternary aromatic carbons. A NOESY signal between HA and HB protons confirmed the Z-configuration.

Coupling with 3-butyn-2-one smoothly generated the corresponding (Z)-3-oxopropylidnephthalides in good to high yields (72–80%) with excellent stereoselectivity. The structure and configuration of compound 3af (entry 32, Table 3) were confirmed by 2D NMR (HMBC and NOESY; SI). Notably, our optimized method generates 3-functionalized-ylidenephthalides in good to excellent yields, accommodating both electron-rich and electron-poor alkynes. The mild reaction conditions also enable the synthesis of phthalide cores with acid- or base-sensitive functionalities at the 3-position, as exemplified by the Boc protecting groups (entries 20–23, Table 3) and ester-containing 3-ylidenephthalides (Table 2).

Coupling/cyclization of diacidic substrates

Having optimized the reaction conditions, we investigated a series of alternative substrates possessing an additional free carboxylic acid group. Typical heteroannulation reactions involving Sonogashira coupling and cyclization are performed under basic conditions, which can be problematic in the presence of free acidic groups. However, as shown in Scheme 2, substrates with an additional free carboxylic acid group on the aryl ring (beside the one ortho to the iodo group) successfully generated the corresponding (Z)-3-ylidenephthalides in good to high yield with excellent stereoselectivity. This is, to our knowledge, the first example of such substrates, bearing ionizable groups, being coupled to furnish (Z)-3-ylidenephthalides.
image file: d5ob00808e-s2.tif
Scheme 2 Coupling/cyclization of a diacidic substrate with alkynes using our Cu2O-catalyzed method.

Scalability

To assess the scalability, we performed a gram-scale synthesis of (Z)-3-ylidenephthalide 2a from 2-iodobenzoic acid (1a). This demonstrated the potential of our Cu2O-mediated method for larger scale applications. The coupling and cyclization of 1a (1 g, 4.03 mmol) with ethyl propiolate (0.4 mL, 4.03 mmol) in 6 mL of DMF, after heating in the presence of Cu2O (30 mol%) at 100 °C for 8 h, afforded 2a in 84% isolated yield.

Proposed reaction mechanism

Based on these results and our previous studies on the same catalytic system,35 we propose the following mechanism as depicted in Scheme 3 for the formation of (Z)-3-ylidenephthalides. The catalytic cycle initiates with the coordination of the terminal alkyne to the heterogeneous Cu2O catalyst surface. At the Cu(I) sites on this surface, the alkyne undergoes deprotonation. This step is facilitated by the intrinsic basicity of surface oxygen atoms or trace CuOH species present on the catalyst, leading to the formation of a surface-bound Cu–alkynyl species. Although DMF decomposition at high temperatures can produce small amounts of Me2NH, which might aid alkyne deprotonation, Cu2O's intrinsic basicity is sufficient, as evidenced by partial conversion in toluene (Table 1, entry 17). Our base-free conditions (100–130 °C) offer a simpler and more cost-effective alternative to base-mediated room-temperature methods, while also avoiding side reactions with acid-sensitive substrates. For safety, reactions were conducted below DMF's decomposition threshold (∼150 °C) in pressure-relief borosilicate vials within a well-ventilated fume hood.
image file: d5ob00808e-s3.tif
Scheme 3 Proposed mechanism for the formation of (Z)-3-ylidenephthalides from 2-iodobenzoic acids and alkynes in the presence of Cu2O.

Subsequently, the surface-bound Cu–alkynyl species participates in a C–C coupling with an aryl iodide (Ar–I), which is also adsorbed and activated on the Cu2O surface via the C–I cleavage. Specifically, 2-iodobenzoic acid reacts with the Cu2O surface through coordination of its ortho-carboxylic acid group to Cu(I) sites. This spatial arrangement positions the C–I bond of 2-iodobenzoic acid in close proximity to surface-bound Cu–alkynyl species, enabling an insertion reaction. This entire process occurs on the catalyst surface, leveraging the unique environment of neighboring Cu and O sites within Cu2O to stabilize the transition state. This leads to the formation of aryl–Cu–alkynyl surface-bound intermediates followed by reductive elimination to yield the 2-alkynylbenzoic acid intermediate.

The coordination of the carboxylic acid plays a crucial role in directing the subsequent cyclization step. The observed 5-exo-dig cyclization is attributed to the proximity of the coordinated carboxylate oxygen to the Cu-activated triple bond. Adjacent copper(I) species further stabilize transition state on the surface, rendering the alkyne more electrophilic and facilitating nucleophilic attack by the carboxylic group, resulting in the formation of the five-membered phthalide ring. This preference for 5-exo-dig over 6-endo-dig cyclization arises from the geometric constraints imposed by the carboxylic acid's coordination to Cu2O, which favors the closure of the smaller five-membered ring. This observation is consistent with a previous report by Uchiyama and co-workers,29a demonstrating that such cyclization reactions of 2-alkynyl-benzoic acid under basic conditions favor 5-exo-dig phthalide formation.

Unlike the method developed by Kumar et al.,30b which reported poor regioselectivity for meta-substituted 2-iodobenzoic acids due to competing 6-endo-dig cyclization, our Cu2O-mediated protocol exclusively affords (Z)-3-ylidenephthalides (5-exo-dig) in high yields (71–82%, Table 2, entries 9–13). This enhanced regioselectivity is likely due to the Cu2O surface's ability to direct cyclization via carboxylate coordination, thus preventing isocoumarin formation. The Cu2O surface stabilizes the transition state, ensuring efficient phthalide production. Unlike other copper species tested, Cu2O's superiority as a catalyst in our methodology likely stems from its heterogeneous surface featuring Cu(I) sites and inherent mild basicity. This combination effectively facilitates alkyne deprotonation, stabilizes the C–C coupling transition state, and promotes subsequent cyclization. DMF was proved to be the best solvent with 90% conversion (entry 3), while very little or no conversion was observed for solvents such as methanol, THF, and toluene (entries 11–17).

The cyclized Cu–carbon intermediate undergoes cleavage via protonation to release (Z)-3-ylidenephthalide. Potential proton sources include residual water, carboxylic acid, or solvent-derived species. This protonation regenerates the Cu2O surface in its Cu(I) form, allowing the catalytic cycle to continue. This overall process efficiently generates (Z)-3-ylidenephthalides with diverse functionalities at the 3-position, without detectable intermediates or by-products, consistent with a concerted, surface-mediated mechanism.

In summary, we have developed a simple and efficient method for the synthesis of (Z)-3-ylidenephthalides from readily available 2-iodobenzoic acids and diverse terminal alkynes. This process provides one of the simplest routes to this valuable class of phthalide analogs, utilizing copper(I) oxide as a catalyst in DMF, without the need for palladium, bases, or ligands. This user-friendly method offers a practical approach to a variety of 3-ylidenephthalides via a tandem coupling/cyclization sequence, without requiring rigorous exclusion of moisture or air. A series of diversely substituted 3-functionalized phthalides was obtained via 5-exo-dig cyclization, exclusively yielding the Z-configuration. Characterized by mild reaction conditions and good to excellent yields, this protocol should be highly attractive for large scale industrial applications and medicinal chemistry efforts.

Experimental section

General procedure for copper(I)-mediated coupling and cyclization reaction

A mixture of 2-iodobenzoic acid (1.0 equivalent), alkyne (1–1.5 equivalents), and copper(I) oxide (0.3 equivalents) in DMF (1.5 mL per 1 mmol of 2-iodobenzoic acid) was heated to 100–130 °C for 8–18 h within a well-ventilated fume hood. After cooling to room temperature, the reaction mixture was quenched with either saturated NH4Cl (for N-Boc-propargylamine) or 1 N HCl and extracted with ethyl acetate. The combined organic extracts were dried over anhydrous Na2SO4, concentrated under reduced pressure, and the resulting residue was purified by flash chromatography using an ethyl acetate/hexane gradient to afford the desired product.

Author contributions

A. R. A. proposed and optimized the synthetic method, synthesized and characterized all compounds, and wrote the initial draft of the manuscript. L. H. secured funding and supervised the project. All authors discussed the experiments, commented and edited the manuscript.

Conflicts of interest

The authors declare no competing financial interest.

Data availability

The data supporting this article have been included as part of the SI.

Supplementary information containing experimental details and characterization data of the new compounds as well as copies of 1H and 13C NMR spectra with HRMS data of all new compounds are available. See DOI: https://doi.org/10.1039/d5ob00808e.

References

  1. (a) L. M. Bedoya, E. del Olmo, R. Sancho, B. Barboza, M. Beltran, A. E. Garcia-Cadenas, S. Sanchez-Palomino, J. L. Lopez-Perez, E. Munoz, A. San Feliciano and J. Alcami, Bioorg. Med. Chem. Lett., 2006, 16, 4075–4079 CrossRef CAS PubMed; (b) T. H. Chou, I. S. Chen, T. L. Hwang, T. C. Wang, T. H. Lee, L. Y. Cheng, Y. C. Chang, J. Y. Cho and J. J. Chen, J. Nat. Prod., 2008, 71, 1692–1695 CrossRef CAS.
  2. (a) M. Yoshikawa, E. Uchida, N. Chatani, N. Murakami and J. Yamahara, Chem. Pharm. Bull., 1992, 40, 3121–3123 CrossRef CAS; (b) K. Umehara, M. Matsumoto, M. Nakamura, T. Miyase, M. Kuroyanagi and H. Noguchi, Chem. Pharm. Bull., 2000, 48, 566–567 CrossRef CAS.
  3. (a) T. Naito, K. Niitsu, Y. Ikeya, M. Okada and H. Mitsuhashi, Phytochemistry, 1992, 31, 1787–1789 CrossRef CAS; (b) F. Bellina, D. Ciucci, P. Vergamini and R. Rossi, Tetrahedron, 2000, 56, 2533–2545 CrossRef CAS; (c) F. Bohlmann, M. A. Metwally and J. Jakupovic, Phytochemistry, 1984, 23, 1975–1977 CrossRef CAS.
  4. G.-L. Zhang, G. Rücker, E. Breitmaier, M. Nieger, R. Mayer and C. Steinbeck, Phytochemistry, 1995, 40, 299–305 CrossRef CAS.
  5. (a) G. Ortar, A. Schiano Moriello, E. Morera, M. Nalli, V. Di Marzo and L. De Petrocellis, Bioorg. Med. Chem. Lett., 2013, 23, 5614–5618 CrossRef CAS PubMed; (b) V. Rukachaisirikul, A. Rodglin, Y. Sukpondma, S. Phongpaichit, J. Buatong and J. Sakayaroj, J. Nat. Prod., 2012, 75, 853–858 CrossRef CAS; (c) H. Yang, G. Y. Hu, J. Chen, Y. Wang and Z. H. Wang, Bioorg. Med. Chem. Lett., 2007, 17, 5210–5213 CrossRef CAS PubMed.
  6. S. F. Brady, M. M. Wagenaar, M. P. Singh, J. E. Janso and J. Clardy, Org. Lett., 2000, 2, 4043–4046 CrossRef CAS.
  7. A. Arnone, G. Assante, G. Nasini, S. Strada and A. Vercesi, J. Nat. Prod., 2002, 65, 48–50 CrossRef CAS.
  8. K. Yoganathan, C. Rossant, S. Ng, Y. Huang, M. S. Butler and A. D. Buss, J. Nat. Prod., 2003, 66, 1116–1117 CrossRef CAS.
  9. (a) M. L. Patil, H. B. Borate, D. E. Ponde and V. H. Deshpande, Tetrahedron, 2002, 58, 6615–6620 CrossRef CAS; (b) D. Mal and P. Pahari, Chem. Rev., 2007, 107, 1892–1918 CrossRef CAS PubMed.
  10. (a) H. S. Ibrahim, W. M. Eldehna, H. A. Abdel-Aziz, M. M. Elaasser and M. M. Abdel-Aziz, Eur. J. Med. Chem., 2014, 85, 480–486 CrossRef CAS; (b) A. Quemener, M. Maillasson, L. Arzel, B. Sicard, R. Vomiandry, E. Mortier, D. Dubreuil, Y. Jacques, J. Lebreton and M. Mathe-Allainmat, J. Med. Chem., 2017, 60, 6249–6272 CrossRef CAS; (c) R. Karmakar, P. Pahari and D. Mal, Chem. Rev., 2014, 114, 6213–6284 CrossRef CAS PubMed.
  11. Z. Chen, S. Wang, K. Liu, R. Zhang, Q. Li, W. Bian, R. Qiao and C. Li, ACS Omega, 2022, 7, 6313–6321 CrossRef CAS PubMed.
  12. (a) D. Riendeau, M. D. Percival, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, J. P. Falgueyret, A. W. Ford-Hutchinson, R. Gordon, G. Greig, M. Gresser, J. Guay, S. Kargman, S. Leger, J. A. Mancini, G. O'Neill, M. Ouellet, I. W. Rodger, M. Therien, Z. Wang, J. K. Webb, E. Wong and C. C. Chan, et al., Br. J. Pharmacol., 1997, 121, 105–117 CrossRef CAS; (b) C.-S. Li, W. C. Black, C. Brideau, C. Chi Chung, S. Charleson, W. A. Cromlish, D. Claveau, J. Y. Gauthier, R. Gordon, G. Greig, E. Grimm, J. Guay, C. K. Lau, D. Riendeau, M. Thérien, D. M. Visco, E. Wong, X. Lijing and P. Prasit, Bioorg. Med. Chem. Lett., 1999, 9, 3181–3186 CrossRef CAS; (c) Y. Leblanc, P. Roy, S. Boyce, C. Brideau, C. C. Chan, S. Charleson, R. Gordon, E. Grimm, J. Guay, S. Léger, C. S. Li, D. Riendeau, D. Visco, Z. Wang, J. Webb, L. J. Xu and P. Prasit, Bioorg. Med. Chem. Lett., 1999, 9, 2207–2212 CrossRef CAS.
  13. (a) L. Yin and J. Liebscher, Chem. Rev., 2007, 107, 133–173 CrossRef CAS; (b) M. A. Andrade and L. Martins, Molecules, 2020, 25, 5506 CrossRef CAS PubMed; (c) K. C. Nicolaou, P. G. Bulger and D. Sarlah, Angew. Chem., Int. Ed., 2005, 44, 4442–4489 CrossRef CAS.
  14. (a) K. Sonogashira, Y. Tohda and N. Hagihara, Tetrahedron Lett., 1975, 16, 4467–4470 CrossRef; (b) R. Chinchilla and C. Najera, Chem. Rev., 2007, 107, 874–922 CrossRef CAS PubMed; (c) R. Chinchilla and C. Najera, Chem. Soc. Rev., 2011, 40, 5084–5121 RSC.
  15. (a) M. B. Thathagar, J. Beckers and G. Rothenberg, Green Chem., 2004, 6, 215–218 RSC; (b) J. H. Li, J. L. Li, D. P. Wang, S. F. Pi, Y. X. Xie, M. B. Zhang and X. C. Hu, J. Org. Chem., 2007, 72, 2053–2057 CrossRef CAS PubMed; (c) F. Monnier, F. Turtaut, L. Duroure and M. Taillefer, Org. Lett., 2008, 10, 3203–3206 CrossRef CAS; (d) H. Plenio, Angew. Chem., Int. Ed., 2008, 47, 6954–6956 CrossRef CAS; (e) M. Carril, A. Correa and C. Bolm, Angew. Chem., Int. Ed., 2008, 47, 4862–4865 CrossRef CAS; (f) E. Zuidema and C. Bolm, Chem. – Eur. J., 2010, 16, 4181–4185 CrossRef CAS PubMed.
  16. (a) M. M. Kayser, K. L. Hatt and D. L. Hooper, Can. J. Chem., 1992, 70, 1985–1996 CrossRef CAS; (b) J. Zhu and M. M. Kayser, Synth. Commun., 1994, 24, 1179–1186 CrossRef CAS; (c) D. T. Mowry, E. L. Ringwald and M. Renoll, J. Am. Chem. Soc., 2002, 71, 120–122 CrossRef; (d) N. Dussart, H. V. Trinh and D. Gueyrard, Org. Lett., 2016, 18, 4790–4793 CrossRef CAS.
  17. J. Munin, E. Quezada, D. Vina, E. Uriarte, G. L. Delogu and J. Gil-Longo, Future Med. Chem., 2019, 11, 179–191 CrossRef CAS.
  18. (a) S. N. Naik, B. Pandey and N. R. Ayyangar, Synth. Commun., 1988, 18, 625–632 CrossRef CAS; (b) K. Maruyama and A. Osuka, J. Org. Chem., 2002, 45, 1898–1901 CrossRef; (c) P. Langer, S. Mkrtchyan, Z. Chilingaryan, G. Ghazaryan, R. Dede, N. Rasool, M. Rashid, A. Villinger, H. Görls, G. Karapetyan, T. Ghochikyan and A. Saghiyan, Synthesis, 2011, 2281–2290 CrossRef.
  19. (a) N. Yasmin and J. K. Ray, RSC Adv., 2013, 3, 25631–25635 RSC; (b) J. He, J. Zhang, X. Li, H. Shi and Y. Du, Chem. Commun., 2022, 58, 9096–9099 RSC.
  20. (a) X. Wang, G. Li, X. Zhang, Z. Feng, J. Jiang, Y. Yang and P. Zhang, Tetrahedron Lett., 2020, 61, 151734 CrossRef CAS; (b) X. He and F. Xue, Tetrahedron Lett., 2014, 55, 1956–1958 CrossRef CAS.
  21. (a) X.-D. Fei, T. Tang, Z.-Y. Ge and Y.-M. Zhu, Synth. Commun., 2013, 43, 3262–3271 CrossRef CAS; (b) X. D. Fei, Z. Y. Ge, T. Tang, Y. M. Zhu and S. J. Ji, J. Org. Chem., 2012, 77, 10321–10328 CrossRef CAS PubMed.
  22. (a) P. G. Ciattini, G. Mastropietro, E. Morera and G. Ortar, Tetrahedron Lett., 1993, 34, 3763–3766 CrossRef CAS; (b) Q. Yuan, Z. B. Chen, F. L. Zhang and Y. M. Zhu, Org. Biomol. Chem., 2017, 15, 1628–1635 RSC.
  23. (a) G. Danoun, P. Mamone and L. J. Goossen, Chem. – Eur. J., 2013, 19, 17287–17290 CrossRef CAS PubMed; (b) D. Nandi, D. Ghosh, S. J. Chen, B. C. Kuo, N. M. Wang and H. M. Lee, J. Org. Chem., 2013, 78, 3445–3451 CrossRef CAS PubMed; (c) M. Zhang, H. J. Zhang, T. Han, W. Ruan and T. B. Wen, J. Org. Chem., 2015, 80, 620–627 CrossRef CAS; (d) Y. Liu, Y. Yang, Y. Shi, X. Wang, L. Zhang, Y. Cheng and J. You, Organometallics, 2016, 35, 1350–1353 CrossRef CAS; (e) W.-J. Han, F. Pu, J. Fan, Z.-W. Liu and X.-Y. Shi, Adv. Synth. Catal., 2017, 359, 3520–3525 CrossRef CAS.
  24. A. A. Almasalma and E. Mejía, Eur. J. Org. Chem., 2018, 188–195 CrossRef CAS.
  25. (a) J. Li, E. Chin, A. S. Lui and L. Chen, Tetrahedron Lett., 2010, 51, 5937–5939 CrossRef CAS; (b) J. H. Park, S. V. Bhilare and S. W. Youn, Org. Lett., 2011, 13, 2228–2231 CrossRef CAS PubMed.
  26. D. Ding, T. Mou, J. Xue and X. Jiang, Chem. Commun., 2017, 53, 5279–5282 RSC.
  27. (a) H.-Y. Liao and C.-H. Cheng, J. Org. Chem., 2002, 60, 3711–3716 CrossRef; (b) H. Sashida, Synthesis, 1999, 1145–1148 CrossRef CAS; (c) C. E. Castro, E. J. Gaughan and D. C. Owsley, J. Org. Chem., 2002, 31, 4071–4078 CrossRef; (d) E. Marchal, P. Uriac, B. Legouin, L. Toupet and P. v. d. Weghe, Tetrahedron, 2007, 63, 9979–9990 CrossRef CAS; (e) B. Y. W. Man, A. Knuhtsen, M. J. Page and B. A. Messerle, Polyhedron, 2013, 61, 248–252 CrossRef CAS; (f) R. Mancuso, C. S. Pomelli, P. Chiappetta, K. F. Gioia, A. Maner, N. Marino, L. Veltri, C. Chiappe and B. Gabriele, J. Org. Chem., 2018, 83, 6673–6680 CrossRef CAS PubMed.
  28. M. Biagetti, F. Bellina, A. Carpita, P. Stabile and R. Rossi, Tetrahedron, 2002, 58, 5023–5038 CrossRef CAS.
  29. (a) M. Uchiyama, H. Ozawa, K. Takuma, Y. Matsumoto, M. Yonehara, K. Hiroya and T. Sakamoto, Org. Lett., 2006, 8, 5517–5520 CrossRef CAS PubMed; (b) C. Kanazawa and M. Terada, Tetrahedron Lett., 2007, 48, 933–935 CrossRef CAS.
  30. (a) T. Ponpandian and S. Muthusubramanian, Tetrahedron Lett., 2012, 53, 4248–4252 CrossRef CAS; (b) M. R. Kumar, F. M. Irudayanathan, J. H. Moon and S. Lee, Adv. Synth. Catal., 2013, 355, 3221–3230 CrossRef CAS.
  31. (a) L. Zhou and H.-F. Jiang, Tetrahedron Lett., 2007, 48, 8449–8452 CrossRef CAS; (b) D. Rambabu, G. P. Kumar, B. D. Kumar, R. Kapavarapu, M. V. B. Rao and M. Pal, Tetrahedron Lett., 2013, 54, 2989–2995 CrossRef CAS; (c) S. Dhara, R. Singha, M. Ghosh, A. Ahmed, Y. Nuree, A. Das and J. K. Ray, RSC Adv., 2014, 4, 42604–42607 RSC; (d) S. Chaudhary, B. R. K. Shyamlal, L. Yadav, M. K. Tiwari and K. Kumar, RSC Adv., 2018, 8, 23152–23162 RSC.
  32. (a) J. E. Baldwin, J. Chem. Soc., Chem. Commun., 1976, 734–736,  10.1039/c39760000734; (b) C. D. Johnson, Acc. Chem. Res., 2002, 26, 476–482 CrossRef.
  33. M. Jithunsa, M. Ueda and O. Miyata, Org. Lett., 2011, 13, 518–521 CrossRef CAS PubMed.
  34. A. R. Ali and L. Hu, Asian J. Org. Chem., 2025, 14, e202400421 CrossRef CAS PubMed.
  35. (a) J. Pospisil, C. Muller and A. Furstner, Chem. – Eur. J., 2009, 15, 5956–5968 CrossRef CAS PubMed; (b) T. S. Mei, R. Giri, N. Maugel and J. Q. Yu, Angew. Chem., Int. Ed., 2008, 47, 5215–5219 CrossRef CAS.
  36. C. E. Castro, R. Havlin, V. K. Honwad, A. M. Malte and S. W. Moje, J. Am. Chem. Soc., 2002, 91, 6464–6470 CrossRef.
  37. C. Niebel, V. Lokshin, M. Sigalov, P. Krief and V. Khodorkovsky, Eur. J. Org. Chem., 2008, 3689–3699 CrossRef CAS.
  38. S. K. Gadakh and A. Sudalai, RSC Adv., 2014, 4, 57658–57661 RSC.

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.